ProMetic and Blue Blood of Taiwan form strategic alliance to develop plasma-derived drugs
13-Jun-2007
The alliance between the two companies will initially target hyperimmune Cytomegalovirus (CMV), as well as two other high value therapeutics, with Taiwan and Southeast Asia as the primary markets. Although the financial details of the alliance were not disclosed, ProMetic and Blue Blood will share in the revenue derived from the sales of products.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.